VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2018 | CAR T-cells: targeting BCMA

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, speaks about his excitement over the CRB-401 study (NCT02658929), which uses anti-BCMA CAR T-cell agent bb2121 for refractory multiple myeloma (MM). BCMA targeting represents a new area for CAR T-cells, and Dr Grupp emphasizes the importance of these positive findings in MM and other hematological malignancies.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter